These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15705066)

  • 21. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density.
    Yildirim U; Erdem H; Kayikci A; Sahin AF; Uzunlar AK; Albayrak A
    J Int Med Res; 2010; 38(5):1689-99. PubMed ID: 21309483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells.
    Chodak GW; Scheiner CJ; Zetter BR
    N Engl J Med; 1981 Oct; 305(15):869-74. PubMed ID: 6168909
    [No Abstract]   [Full Text] [Related]  

  • 24. Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven.
    Reuter VE
    J Clin Oncol; 2005 Sep; 23(27):6450-1. PubMed ID: 16129842
    [No Abstract]   [Full Text] [Related]  

  • 25. [Correlation of clusterin expression to prognosis of bladder carcinoma].
    Luo JH; Xie D; Chen W; Dai YP; Li XF; Tao Y; Zheng KL
    Ai Zheng; 2005 Jun; 24(6):743-7. PubMed ID: 15946493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer.
    Colabufo NA; Berardi F; Contino M; Ferorelli S; Niso M; Perrone R; Pagliarulo A; Saponaro P; Pagliarulo V
    Cancer Lett; 2006 Jun; 237(1):83-8. PubMed ID: 16005143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof].
    Yu L; Chen XJ; Shi PQ; Ding Q; Sun CH; Liu GB; Shi DM; Huang YG
    Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2683-4. PubMed ID: 19080686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
    Das K; Zhao Y; Sugiono M; Lau W; Tan PH; Cheng C
    Urol Oncol; 2007; 25(4):317-21. PubMed ID: 17628298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial comment.
    Kamat AM; Svatek R
    J Urol; 2009 Dec; 182(6):2630; discussion 2631. PubMed ID: 19836780
    [No Abstract]   [Full Text] [Related]  

  • 30. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.
    Clairotte A; Lascombe I; Fauconnet S; Mauny F; Félix S; Algros MP; Bittard H; Kantelip B
    Am J Clin Pathol; 2006 Jan; 125(1):119-26. PubMed ID: 16483000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible role of nuclear factor kappaB detected by in situ hybridization in the pathogenesis of transitional cell carcinoma of the bladder.
    Kadhim HS; Al-Jeboori TI; Tawfik MS
    J Med Liban; 2006; 54(4):196-9. PubMed ID: 17330371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathways in bladder cancer.
    Williams SG; Stein JP
    Urol Res; 2004 Dec; 32(6):373-85. PubMed ID: 15551095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Smad4 and TGF-beta1 expression and clinical significance in bladder transitional cell carcinoma].
    Tang ZY; Yang LY; Zhang YJ; Peng KL; Qi L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):363-6. PubMed ID: 16859125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
    Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
    J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemo-angiogenic profile of bovine urinary bladder tumors distinguishes urothelial carcinomas from hemangiosarcomas.
    Carvalho T; Elias AP; Nunes T; Peleteiro MC; Dias S
    Vet Immunol Immunopathol; 2008 Feb; 121(3-4):344-58. PubMed ID: 18022698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
    Zhou JT; Cai ZM; Li NC; Na YQ
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
    Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
    Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
    Mitra AP; Datar RH; Cote RJ
    J Clin Oncol; 2006 Dec; 24(35):5552-64. PubMed ID: 17158541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer.
    Atlasi Y; Mowla SJ; Ziaee SA
    Cancer Detect Prev; 2009; 32(4):308-13. PubMed ID: 19186007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.